Previous 10 | Next 10 |
2024-03-06 12:54:39 ET More on Gilead Sciences, Merck Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript) Gilead's Business Development: ...
– Week 24 Results Support Continued Development as a Potential Long-Acting Oral Combination Treatment Option in Virologically Suppressed People with HIV – – Novel Investigational Combination Regimen has the Potential to be the First Oral Weekly HIV Treatment, Help...
2024-03-06 10:01:18 ET More on Gilead, Merus, etc. Gilead Sciences, Inc. (GILD) Presents at TD Cowen 44th Annual Health Care Conference (Transcript) Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Gilead's Business Development: The Good, The ...
– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover nov...
– Veklury Was Associated With a Lower Risk of Developing Long-COVID in One Analysis – – Veklury Was Associated With a Reduced Risk of Mortality Among People Who Are Immunocompromised in a Separate Analysis – Gilead Sciences, Inc. (Nasdaq: GILD) ...
– New Positive Clinical Data Demonstrate Momentum on Investigational Once-Daily, Once-Weekly and Twice-Yearly Dosing Strategies – – Key Findings from Studies Evaluating Potential Future Long-Acting Combination Regimens Affirm Commitment to Continuous Biomedica...
2024-03-05 15:39:10 ET Gilead Sciences, Inc. (GILD) TD Cowen 44th Annual Health Care Conference March 05, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Presentation...
2024-03-05 10:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting February 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling...
NORTHAMPTON, MA / ACCESSWIRE / March 5, 2024 / Gilead Sciences Originally published by SAN FRANCISCO BUSINESS TIMES on bizjournals.com Much has changed since Daniel O'Day, chairman and CEO, arrived at Gilead Sciences in 2019. The company has grown considerably and expanded on its long-standin...
NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...